531 A Phase 1b multi-tumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors: results of the triple-negative breast cancer, ovarian cancer, and endometrial cancer cohorts

• Vivek Subbiah,
• Capucine Baldini,
• Kristen Spencer,
• Luis Manso,
• Armando Santoro,
• Sandip Patel,
• Joaquina Baranda,
• Ira Winer,
• Akhila Wimalasingham,
• Linda Duska,
• Polina Khrizman,
• Griet Van Lancker,
• Lana Andrianova,
• Sumandeep Atwal,
• Keerti Sharma

Affiliations

Vivek Subbiah

Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Capucine Baldini

5Institut de Cancérologie Gustave Roussy, Villejuif, France

Kristen Spencer

Aff2 grid.430387.b0000000419368796Rutgers Cancer Institute of New Jersey 195 Little Albany Street 08901 New Brunswick NJ USA

Luis Manso

Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain

Armando Santoro

Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy

Sandip Patel

3University of California at San Diego, La Jolla, California, USA

Joaquina Baranda

2University of Kansas Cancer Center, Kansas City, KS, USA

Ira Winer

1Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA

Akhila Wimalasingham

2Queen Mary University of London, London, UK

Linda Duska

7University of Virginia, Charlottesville, VA, USA

Polina Khrizman

10MD Anderson Cancer Center at Cooper, Camden, NJ, USA

Griet Van Lancker

11Ghent University, Ghent, Belgium

Lana Andrianova

12Exelixis, Inc., Alameda, CA, USA

Sumandeep Atwal

12Exelixis, Inc., Alameda, CA, USA

Keerti Sharma

12Exelixis, Inc., Alameda, CA, USA